{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:46:02Z","timestamp":1761176762914,"version":"build-2065373602"},"reference-count":37,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The three main chemotherapy regimens for people with unresectable pancreatic cancer include modified FOLFIRINOX (comprising oxaliplatin, irinotecan and fluorouracil, denoted mFFX), gemcitabine with nab\u2010paclitaxel (GnP), and single\u2010agent gemcitabine (GEM). We explored characteristics associated with the type of chemotherapy and variations in survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Records for people with unresected pancreatic adenocarcinoma between 2018 and 2022 treated with first\u2010line mFFX, GnP or GEM were extracted from the population\u2010based Queensland Oncology Repository. Multivariable Poisson models were fitted to determine factors associated with each type of chemotherapy, expressed as relative likelihoods (RLs). Variations in three\u2010year observed survival were assessed using flexible parametric modelling and reported in terms of adjusted excess mortality hazard ratios (HRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 766 people in the study cohort, 59% were treated with GnP, 27% with mFFX, and 15% with GEM. After adjustment, treatment with mFFX was far more likely in selected private facilities compared to public hospitals (RL\u2009=\u20092.33, 95% CI 1.84\u20132.96), whereas the GEM regimen was used more often for those from outer regional\/remote areas (RL\u2009=\u20092.20 compared to people living in major cities, 95% CI 1.45\u20133.34;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Three\u2010year survival was very poor at just 5% (95% CI 3%\u20137%). Nonetheless, adjusted mortality was higher for GnP (HR\u2009=\u20091.30, 95% CI 1.07\u20131.59) and GEM (HR\u2009=\u20091.53, 95% CI 1.17\u20132.01) compared to mFFX.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Apart from clinical indications, there should be equity in the treatment received for unresectable pancreatic cancer. Our results suggest, however, that where a person lives and the type of facility at which they are treated may influence their chemotherapy regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71226","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:15:47Z","timestamp":1757326547000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018\u20132022"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2721-9083","authenticated-orcid":false,"given":"Danny R.","family":"Youlden","sequence":"first","affiliation":[{"name":"Cancer Alliance Queensland Metro South Health  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan A.","family":"Chan","sequence":"additional","affiliation":[{"name":"Adem Crosby Cancer Centre, Department of Medical Oncology, Division of Cancer Care Services Sunshine Coast University Hospital  Birtinya Queensland Australia"},{"name":"School of Medicine and Dentistry Griffith University  Birtinya Queensland Australia"},{"name":"Centre for Bioinnovation University of the Sunshine Coast  Sippy Downs Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Clark","sequence":"additional","affiliation":[{"name":"Cancer Alliance Queensland Metro South Health  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria K.","family":"Donoghue","sequence":"additional","affiliation":[{"name":"Cancer Alliance Queensland Metro South Health  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5091-5995","authenticated-orcid":false,"given":"Michael J.","family":"Allen","sequence":"additional","affiliation":[{"name":"Adem Crosby Cancer Centre, Department of Medical Oncology, Division of Cancer Care Services Sunshine Coast University Hospital  Birtinya Queensland Australia"},{"name":"School of Medicine and Dentistry Griffith University  Birtinya Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_10_3_1","unstructured":"J.Ferlay M.Ervik F.Lam et\u00a0al. \u201cGlobal Cancer Observatory: Cancer Today (Version 1.1) \u201d(Lyon France: International Agency for Research on Cancer 2024) https:\/\/gco.iarc.who.int\/today."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2022.07.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00141-0"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308653"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2016.05.011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216391"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30347-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.259"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092584"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i43.4846"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231154711"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002234"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006004"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30110694"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-45"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1839-4655.2014.tb00322.x"},{"volume-title":"TNM Classification of Malignant Tumours","year":"2016","author":"Brierley J. D.","key":"e_1_2_10_21_1"},{"key":"e_1_2_10_22_1","unstructured":"Australian Bureau of Statistics \u201cAustralian Statistical Geography Standard (ASGS) Edition 3 \u201d(Canberra Australia: ABS 2021)."},{"key":"e_1_2_10_23_1","unstructured":"Australian Bureau of Statistics \u201cSocio\u2010Economic Indexes for Areas (SEIFA) Australia \u201d(Canberra Australia: ABS 2023) https:\/\/www.abs.gov.au\/statistics\/people\/people\u2010and\u2010communities\/socio\u2010economic\u2010indexes\u2010areas\u2010seifa\u2010australia\/latest\u2010release."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"volume-title":"Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model","year":"2011","author":"Royston P.","key":"e_1_2_10_25_1"},{"key":"e_1_2_10_26_1","unstructured":"Australian Bureau of Statistics \u201cNational State and Territory Population \u201d(Canberra Australia: ABS 2023) https:\/\/www.abs.gov.au\/statistics\/people\/population\/national\u2010state\u2010and\u2010territory\u2010population\/dec\u20102023."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-06-19-4957"},{"key":"e_1_2_10_28_1","unstructured":"National Guideline Alliance (UK) \u201cManagement of Unresectable Pancreatic Cancer \u201dIn: Pancreatic Cancer in Adults: Diagnosis and Management (NICE Guideline No 85) (London: National Institute for Health and Care Excellence (NICE) 2018)."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08605-x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111372"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-017-0028-5"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13353-2"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.05.002"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14961"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12662"},{"key":"e_1_2_10_36_1","unstructured":"The State of Queensland (Queensland Audit Office) \u201cHealth Outcomes for First Nations People (Report 14: 2022\u201323) \u201d(2023)."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.00190"},{"key":"e_1_2_10_38_1","unstructured":"Cancer Australia \u201cAustralian Cancer Plan \u201d(Sydney: CA 2023) https:\/\/www.australiancancerplan.gov.au\/populations\/people\u2010living\u2010in\u2010rural\u2010and\u2010remote\u2010areas."}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:32:26Z","timestamp":1761129146000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cam4.71226"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71226","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71226"}}